Implementing Pharmacogenomics Testing : Single Center Experience at Arkansas Children's Hospital
Pharmacogenomics (PGx) is a growing field within precision medicine. Testing can help predict adverse events and sub-therapeutic response risks of certain medications. To date, the US FDA lists over 280 drugs which provide biomarker-based dosing guidance for adults and children. At Arkansas Children's Hospital (ACH), a clinical PGx laboratory-based test was developed and implemented to provide guidance on 66 pediatric medications for genotype-guided dosing. This PGx test consists of 174 single nucleotide polymorphisms (SNPs) targeting 23 clinically actionable PGx genes or gene variants. Individual genotypes are processed to provide per-gene discrete results in star-allele and phenotype format. These results are then integrated into EPIC- EHR. Genomic indicators built into EPIC-EHR provide the source for clinical decision support (CDS) for clinicians, providing genotype-guided dosing.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of personalized medicine - 11(2021), 5 vom: 11. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gill, Pritmohinder S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Best practice alerts (BPAs) |
|---|
| Anmerkungen: |
Date Revised 15.06.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jpm11050394 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326131620 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326131620 | ||
| 003 | DE-627 | ||
| 005 | 20231225193931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jpm11050394 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1087.xml |
| 035 | |a (DE-627)NLM326131620 | ||
| 035 | |a (NLM)34064668 | ||
| 035 | |a (PII)394 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gill, Pritmohinder S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Implementing Pharmacogenomics Testing |b Single Center Experience at Arkansas Children's Hospital |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.06.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Pharmacogenomics (PGx) is a growing field within precision medicine. Testing can help predict adverse events and sub-therapeutic response risks of certain medications. To date, the US FDA lists over 280 drugs which provide biomarker-based dosing guidance for adults and children. At Arkansas Children's Hospital (ACH), a clinical PGx laboratory-based test was developed and implemented to provide guidance on 66 pediatric medications for genotype-guided dosing. This PGx test consists of 174 single nucleotide polymorphisms (SNPs) targeting 23 clinically actionable PGx genes or gene variants. Individual genotypes are processed to provide per-gene discrete results in star-allele and phenotype format. These results are then integrated into EPIC- EHR. Genomic indicators built into EPIC-EHR provide the source for clinical decision support (CDS) for clinicians, providing genotype-guided dosing | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a best practice alerts (BPAs) | |
| 650 | 4 | |a clinical decision support (CDS) | |
| 650 | 4 | |a electronic health records (EHR) | |
| 650 | 4 | |a genomic indicators | |
| 650 | 4 | |a genotype | |
| 650 | 4 | |a pediatrics | |
| 650 | 4 | |a pharmacogenomics (PGx) | |
| 650 | 4 | |a phenotype | |
| 700 | 1 | |a Yu, Feliciano B |e verfasserin |4 aut | |
| 700 | 1 | |a Porter-Gill, Patricia A |e verfasserin |4 aut | |
| 700 | 1 | |a Boyanton, Bobby L |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Judy C |e verfasserin |4 aut | |
| 700 | 1 | |a Farrar, Jason E |e verfasserin |4 aut | |
| 700 | 1 | |a Veerapandiyan, Aravindhan |e verfasserin |4 aut | |
| 700 | 1 | |a Prodhan, Parthak |e verfasserin |4 aut | |
| 700 | 1 | |a Bielamowicz, Kevin J |e verfasserin |4 aut | |
| 700 | 1 | |a Sellars, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Burrow, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Kennedy, Joshua L |e verfasserin |4 aut | |
| 700 | 1 | |a Clothier, Jeffery L |e verfasserin |4 aut | |
| 700 | 1 | |a Becton, David L |e verfasserin |4 aut | |
| 700 | 1 | |a Rule, Don |e verfasserin |4 aut | |
| 700 | 1 | |a Schaefer, G Bradley |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of personalized medicine |d 2011 |g 11(2021), 5 vom: 11. Mai |w (DE-627)NLM228113881 |x 2075-4426 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:5 |g day:11 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jpm11050394 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 5 |b 11 |c 05 | ||